Previous 10 | Next 10 |
2023-05-03 17:37:36 ET MorphoSys press release ( NASDAQ: MOR ): Q1 GAAP EPS of -€1.30. Revenue of €62.3M (+50.1% Y/Y). Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023. €79...
– Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 ...
Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on Ma...
- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today anno...
2023-04-13 08:01:47 ET Summary MorphoSys completed enrollment for MANIFEST-2, a Phase 3 study exploring the safety and efficacy of pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients with myelofibrosis. The topline data of the MANIFEST-2 is expected by...
2023-04-05 14:34:00 ET Shares of MorphoSys (NASDAQ: MOR) were up more than 16% Wednesday afternoon after the biopharmaceutical company updated the trials status of the company's lead therapy. The stock is up more than 28% so far this year. The company specializes in therapies to tre...
2023-04-05 11:58:46 ET MorphoSys AG ( NASDAQ: MOR ) added ~16% in the morning hours Wednesday after the German biotech indicated a faster-than-expected timeline for its ongoing late-stage study for experimental therapy, pelabresib, against blood cancer myelofibrosis. The com...
2023-03-16 11:11:16 ET The following slide deck was published by MorphoSys AG in conjunction with their 2022 Q4 earnings call. For further details see: MorphoSys AG 2022 Q4 - Results - Earnings Call Presentation
2023-03-16 11:10:09 ET MorphoSys AG (MOR) Q4 2022 Earnings Conference Call March 16, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer ...
2023-03-15 16:20:36 ET MorphoSys press release ( NASDAQ: MOR ): FY GAAP EPS of €8.93. Revenue of €81.6M (+54.3% Y/Y). Monjuvi U.S. net product sales US$ 80m to 95m For further details see: MorphoSys GAAP EPS of €8.93, reven...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...